Lilly to Present New Data from Oncology Portfolio at ESMO Congress

INDIANAPOLIS , Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio ® (abemaciclib), Retevmo ® (selpercatinib) and CYRAMZA ® (ramucirumab) will be presented at the European Society for Medical Oncology (ESMO) Congress 2021, to be held